Executive Summary
Cannabis Suisse Corp (CSUI) reported a nominal quarterly revenue of $7,500 for QQ3 2024, accompanied by a substantial loss and a severely strained liquidity position. The company posted a net loss of $67,974 and an EBITDA of negative $61,800, with gross profit turning negative at -$437 and a gross margin of -5.83%. Operating income registered -$62,861 and the net income margin stood at -9.06% on the quarter. Cash flow from operations was deeply negative at -$23,430, and free cash flow matched the operating cash burn. The balance sheet reveals a highly leveraged structure with total assets of $525.9 million but total liabilities of $1,002.9 million and negative stockholders’ equity of -$476.98 million, signaling material solvency risk despite a large fixed asset base (PPE of $525.9 million).
The QQ3 2024 result set underscores a fragile near-term financial position, with limited liquidity (current and quick ratios effectively near zero) and a substantial debt load (long-term debt of $593.0 million and total debt of $916.7 million). Management commentary is not provided in the supplied transcript data, limiting insight into strategic pivots or forward-looking guidance. Absent a material improvement in revenue generation or a decisive balance-sheet recapitalization, CSUI faces a prolonged earnings-and-liquidity runway challenge.
Key Performance Indicators
QoQ: -169.81% | YoY:-310.10%
QoQ: -23.98% | YoY:59.72%
QoQ: -24.05% | YoY:57.54%
QoQ: -25.00% | YoY:60.53%
Key Insights
Revenue: $7.50k (YoY +200.0%, QoQ 0.0%)
Gross Profit: -$437 (Gross Margin -5.83%)
Operating Income: -$62.86k (Operating Margin -8.38%)
Net Income: -$67.97k (Net Margin -9.06%)
EPS (diluted): -$0.0015
EBITDA: -$61.80k (EBITDA Margin -8.24%)
Cash Flow from Operations: -$23.43k; Free Cash Flow: -$23.43k
Cash and Cash Equivalents: $44
Total Assets: $525.94M
Total Liabilities: $1,002.91M
Stockholders’ Equity: -$476.98M
Current Ratio: 0.0001; Debt:Total Capitalization: 2.08x; Net Debt: $916.65M
Weig...
Financial Highlights
Revenue: $7.50k (YoY +200.0%, QoQ 0.0%)
Gross Profit: -$437 (Gross Margin -5.83%)
Operating Income: -$62.86k (Operating Margin -8.38%)
Net Income: -$67.97k (Net Margin -9.06%)
EPS (diluted): -$0.0015
EBITDA: -$61.80k (EBITDA Margin -8.24%)
Cash Flow from Operations: -$23.43k; Free Cash Flow: -$23.43k
Cash and Cash Equivalents: $44
Total Assets: $525.94M
Total Liabilities: $1,002.91M
Stockholders’ Equity: -$476.98M
Current Ratio: 0.0001; Debt:Total Capitalization: 2.08x; Net Debt: $916.65M
Weight Avg Shares: 46.25M
Income Statement
| Metric |
Value |
YoY Change |
QoQ Change |
| Revenue |
7.50K |
200.00% |
0.00% |
| Gross Profit |
-437.00 |
-310.10% |
-169.81% |
| Operating Income |
-62.86K |
59.72% |
-23.98% |
| Net Income |
-67.97K |
57.54% |
-24.05% |
| EPS |
0.00 |
60.53% |
-25.00% |
Key Financial Ratios
operatingProfitMargin
-838%
operatingCashFlowPerShare
$-0
Management Commentary
No earnings call transcript or management quotes are provided in the dataset for QQ3 2024. As a result, transcript-based highlights or management quotes could not be incorporated. The analysis relies on the SEC filing data and quarterly results.
Forward Guidance
No formal forward guidance is available in the provided data. Given the QQ3 2024 results, investors should monitor: (1) liquidity runway and potential cash burn; (2) debt maturities and any refinancing plans; (3) potential restructuring of cost structure, especially fixed overheads; (4) evolution of core revenue streams (OTC products, CBD oils, and retail channels) and any diversification gains. Achievability of any new guidance will hinge on revenue stabilization or growth, as well as aggressive balance-sheet optimization.